Jing L. Marantz joined Scholar Rock November 2022 as
Chief Medical Officer, overseeing development and
medical affairs. She has over 20 years of experience in
the biopharmaceutical industry spanning R&D,
business development, and commercial strategy in
multiple specialties and rare diseases. Jing currently
serves on the board of Arcturus Therapeutics (NASDAQ:
ARCT). She was recently EVP and Chief Business Officer
of Krystal Biotech, after serving on its board for a
year. Prior to Krystal, Jing was Senior Vice President
of Medical Affairs at Acceleron Pharma until its
acquisition by Merck & Co., Inc. Jing has held
leadership positions at Alnylam, Alexion, Biogen, ARIAD,
and Millennium Pharmaceuticals across development,
medical affairs, and business development. She was a
management consultant with Strategic Decisions Group and
briefly affiliated with Massachusetts General Hospital
following a post-doctoral fellowship at the Dana-Farber
Cancer Institute. She received her medical training from
Tongji Medical College, a Ph.D. in Biochemistry and
Molecular Biology from Medical University of South
Carolina, and an MBA from the University of California
at Berkeley.
Jing Marantz, M.D., Ph.D., MBA
Chief Medical Officer